|
| |
bimosiamose Pages on BioPortfolio:
BioPortfolio - bimosiamose
Tolerability and pharmacokinetics of inhaled bimosiamose disodium . ... BioPortfolio - bimosiamose BioPortfolio - REVOTAR Biopharmaceuticals AG -
Profile . ...
http://www.bioportfolio.com/search/bimosiamose.html...
|
BioPortfolio - REVOTAR Biopharmaceuticals AG
The Company was endowed from the start with the asset bimosiamose, ... Revotar reports positive Phase I data in psoriasis with its Bimosiamose 5% Cream ...
http://www.bioportfolio.com/biocorporate/29226-REVOTAR_Bioph...
|
BioPortfolio - Dr. Helmut Brunar IKFM-Consulting
BioPortfolio - Dr. Helmut Brunar IKFM -Consulting ... http://www.bioportfolio. com/search/bimosiamose.html. ... http://www.bioportfolio.com/search/IKFM.html
...
http://www.bioportfolio.com/search/Dr._Helmut_Brunar___IKFM-...
|
BioPortfolio - inveresk research tranent
Bimosiamose disodium (Inveresk Research, Tranent, UK) was used as an aqueous solution for inhalation containing 100 mg ml−1 in 5-ml ampoules. ...
http://www.bioportfolio.com/search/inveresk_research_tranent...
|
BioPortfolio - revotar 2008
BioPortfolio - revotar 2008 Revotar Reports Positive Phase I Data in Psoriasis with its Bimosiamose 5% Cream , Therapeutics Daily: Oct 13 . ...
http://www.bioportfolio.com/search/revotar_2008.html...
|
BioPortfolio - sk bio-pharma
BioPortfolio - bimosiamose BioPortfolio - sk biopharma BioPortfolio - bimosiamose ... http://www. ... http://www.bioportfolio.com/search/bimosiamose.
html. ...
http://www.bioportfolio.com/search/sk_bio-pharma.html...
|
BioPortfolio - inveresk.com
Bimosiamose disodium (Inveresk Research, Tranent, UK) was used as an aqueous . . .. BioPortfolio - INVERESK RESEARCH SCOTLAND Bimosiamose disodium (Inveresk ...
http://www.bioportfolio.com/search/inveresk.com.html...
|
BioPortfolio - INSAF - insulin activator factor (insulin control ...
Bimosiamose, an inhaled small-molecule pan-selectin antagonist, attenuates late asthmatic reactions following allergen challenge in mild asthmatics: a ...
http://www.bioportfolio.com/gene/3637-INSAF.html...
|
BioPortfolio - Body Surface Area
In order to evaluate the safety of a new topical formulation of the pan-selectin antagonist Bimosiamose, twenty percent of the body surface area, . ...
http://www.bioportfolio.com/search/Body_Surface_Area.html...
|
BioPortfolio - Insaf - Profile
May;29(5):871-8. Epub 2007 Jan 24. (DOI Direct Link). • Bimosiamose, an inhaled small-molecule pan-selectin antagonist, attenuates late asthmatic reactions ...
http://www.bioportfolio.com/biocorporate/34019-Insaf.pdf...
|
Results from other life science and pharmaceutical sites:
Bimosiamose, an inhaled small-molecule pan-selectin antagonist ...
We evaluated the effect of inhaled bimosiamose (TBC1269), a synthetic pan- selectin antagonist, on allergen-induced late asthmatic reactions (LAR) in mild
...
http://www.ncbi.nlm.nih.gov/pubmed/16140027...
|
Tolerability and pharmacokinetics of inhaled bimosiamose disodium ...
The aim of these first-in-human studies was to investigate the tolerability and the pharmacokinetics of bimosiamose disodium (TBC1269Z) administered by ...
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=22...
|
EFFECTS OF THE PAN-SELECTIN ANTAGONIST BIMOSIAMOSE...[Shock. 2007 ...
PubMed is a service of the US National Library of Medicine that includes over 18 million citations from MEDLINE and other life science journals for ...
http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=ShowD...
|
Revotar Biopharmaceuticals Reports Positive Phase I Data In ...
In order to evaluate the safety of a new topical formulation of the pan-selectin antagonist Bimosiamose, twenty percent of the body surface area, ...
http://www.biospace.com/news_story.aspx?NewsEntityId=112851...
|
Effects of the pan-selectin antagonist bimosiamose (TBC1269) in ...
All subjects received 2 ng/kg of LPS and, 10 min thereafter, a 15-min infusion of either 30 mg/kg of the pan-selectin antagonist bimosiamose or equal ...
http://www.ncbi.nlm.nih.gov/pubmed/18598003...
|
{1} Granted Orphan Drug Designation By The European Medicines ...
9 Jun 2005 ... Bimosiamose is a pan-selectin antagonist, targeted against the selectin ... Its most advanced compound bimosiamose (small molecule selectin ...
http://www.biospace.com/news_story.aspx?NewsEntityId=2038622...
|
Physiochemical properties, safety and pharmacokinetics of ...
OBJECTIVE: Bimosiamose is a novel synthetic panselectin antagonist being developed for the treatment...
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&d...
|
Portfolio-Company, Revotar Biopharmaceuticals Concludes Start-Up ...
Bimosiamose is a new selectin antagonist developed by Revotar for the treatment of ... About Bimosiamose: Within Revotar AG's research and development ...
http://www.biospace.com/news_story.aspx?NewsEntityId=28134...
|
BioPortfolio - REVOTAR Biopharmaceuticals AG
The Company was endowed from the start with the asset bimosiamose, ... Revotar reports positive Phase I data in psoriasis with its Bimosiamose 5% Cream ...
http://www.bioportfolio.com/biocorporate/29226-REVOTAR_Bioph...
|
Revotar Biopharmaceuticals Reports Positive Preclinical Data From ...
Bimosiamose cream (1%, 3%, and 5%) was applied twice daily for 4 months on the skin (10% of total body surface area) of Gottingen minipigs to evaluate the ...
http://www.biospace.com/news_story.aspx?NewsEntityId=115083...
|
|
